1539905
USP
吡格列酮 盐酸盐
United States Pharmacopeia (USP) Reference Standard
别名:
5-[[4-[2-(5-一乙基-2-吡啶)乙氧基]苯基]甲基]-2,4-噻唑烷二酮 单盐酸盐
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C19H20N2O3S · HCl
CAS Number:
分子量:
392.90
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
pioglitazone
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
Cl.CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
InChI
1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H
InChI key
GHUUBYQTCDQWRA-UHFFFAOYSA-N
基因信息
human ... PPARG(5468)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Pioglitazone hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Pioglitazone and Metformin Hydrochloride Tablets
- Pioglitazone Tablets
- Pioglitazone and Glimepiride Tablets
生化/生理作用
盐酸吡格列酮是一种PPARγ激动剂和噻唑烷二酮（TZD）抗糖尿病药物。
盐酸吡格列酮是一种PPARγ激动剂和噻唑烷二酮（TZD）抗糖尿病药物。吡格列酮是一种核受体过氧化物酶体增殖物激活受体γ（PPAR-γ）的选择性激动剂，并在较小程度上是PPAR-α。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Carc. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Chin-Hsiao Tseng
Metabolism: clinical and experimental, 63(8), 1049-1055 (2014-06-04)
To investigate whether pioglitazone treatment of patients with type 2 diabetes mellitus was associated with an increased risk of kidney cancer. The reimbursement databases of all Taiwanese patients with type 2 diabetes who received oral anti-diabetic agents or insulin from
W Xu et al.
Journal of internal medicine, 277(1), 137-150 (2014-07-22)
Progressive β-cell dysfunction hinders the maintenance of glycaemic control in type 2 diabetes, but comparative data on β-cell-protective therapies are lacking in the early stage of type 2 diabetes. Here we evaluated the comparative glycaemic efficacy and impact on β-cell
The use of oral pioglitazone in the treatment of lichen planopilaris.
Natasha Atanaskova Mesinkovska et al.
Journal of the American Academy of Dermatology, 72(2), 355-356 (2015-01-17)
M Suzuki et al.
Nutrition & diabetes, 4, e125-e125 (2014-07-08)
Tofogliflozin, a highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2), induces urinary glucose excretion (UGE), improves hyperglycemia and reduces body weight in patients with Type 2 diabetes (T2D). The mechanisms of tofogliflozin on body weight reduction were investigated in detail
Xiao-qing Chen et al.
Experimental cell research, 330(1), 43-55 (2014-08-26)
The exact mechanisms underlying inhibitory effects of pioglitazone (Pio) on Angiotensin II (AngII)-induced atrial fibrosis are complex and remain largely unknown. In the present study, we examined the effect of Pio on AngII-induced mice atrial fibrosis in vivo and atrial
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持